- Home
- CTRN vs CLLS Comparison
CTRN vs CLLS Comparison
Compare CTRN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRN | CLLS |
|---|---|---|
| Founded | 1946 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.6M | 384.3M |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CTRN | CLLS |
|---|---|---|
| Price | $47.25 | $4.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $52.00 | $8.33 |
| AVG Volume (30 Days) | ★ 91.9K | 37.9K |
| Earning Date | 06-02-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $753,079,000.00 | N/A |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | $5.62 | $0.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.69 | N/A |
| 52 Week Low | $19.12 | $1.33 |
| 52 Week High | $56.78 | $5.48 |
Technical Indicators
Market Signals| Indicator | CTRN | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.34 | 63.19 |
| Support Level | $42.06 | $3.25 |
| Resistance Level | $48.59 | $4.46 |
| Average True Range (ATR) | 2.81 | 0.22 |
| MACD | 0.34 | 0.12 |
| Stochastic Oscillator | 75.40 | 71.16 |
Price Performance
Historical ComparisonAbout CTRN Citi Trends Inc.
Citi Trends Inc is a retailer of urban fashion apparel and accessories in the United States. The company offers apparel, including fashion sportswear for men and women, as well as children, such as newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and functional and decorative home products, as well as beauty products, books and toys.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.